References
- Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588–94
- Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001;28 (Suppl 11):75–80
- Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised placebo-controlled trial. J Clin Oncol 2005;23: 3314–21
- LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001;28 (Suppl 11): 22–7
- Gainford MC, Dranitsaris G, Clemens M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769–73
- National Institute of Health and Clinical Excellence (NICE) (2002) Guidance on Cancer Services: Improving Outcomes in Breast Cancer, Manual Update. Available at: http://guidance. nice.org.uk/csgbc/guidance/pdf/English/download.dspx [Last accessed 19 April 2007]
- ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann Oncol 2005;16 (Suppl 1):i10–12
- Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database of Systemic Reviews, Issue 3, 2006 Art. No.: CD003474. DOI: 10.1002/14651858.CD003474. pub2
- Murray N. Forthcoming UK trials in bisphosphonate therapy in breast cancer. 2005. BMJ letters 6th May 2006. Response to Gainford MC, Dranitsaris G, Clemens M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330: 769–73
- Clemens M, Dranitsaris G, Cole D, et al. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 2006;11:227–33
- Verma S, Kerr-Cresswell D, Dranitsaris G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 2004;12:852–8
- Clemens M, Enright K, Cesta A, et al. Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 2004;11:e168–78
- Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189–95
- Rosen R, Smith A, Harrison A. Future trends and challenges for cancer services in England. A review of the literature and policy. King’s Fund and Cancer Research UK. August 2006
- Perez EA. Metastatic bone disease in breast cancer: the patient’s perspective. Semin Oncol 2001;28(4 Suppl 11):60–3
- Department of Health. Our Health, Our Care, Our Say. London: The Stationery Office, 2006
- Pocock M, King P, Ruth K. A review of bisphosphonate usage in the south west region in patients with a diagnosis of myeloma or MGUS. South West Public Health Observatory. Available at: http://www.swpho.nhs.uk/resource/item.aspx?RID=9212 [Last accessed 20 September 2006]